Stryker has generated an average annual return of 10.3% over the past 20 years, outperforming the market by 1.04% on an annualized basis. The medical technology company currently holds a market capitalization of $122.02 billion. This performance highlights the impact of compounded returns on long-term cash growth for investors.

Investment Growth Analysis

If an investor had purchased $1000 worth of Stryker stock 20 years ago, the value of that investment would have increased significantly. Based on the current share price of $318.62, the initial investment would be worth $7,050.56 today.

Key Performance Metrics

Stryker announced the U.S. commercial launch of Mako RPS for total knee replacement procedures on July 16, 2026. The launch introduces Mako Handheld Robotics, expanding the Mako portfolio beyond robotic-arm assisted surgery into a new category of orthopaedic robotics. The system combines robotic execution, intraoperative planning, and a familiar handheld power tool workflow to bring robotic technology to a new segment of the orthopaedic market.

The Mako RPS is designed to provide surgeons with an intuitive handheld robotic experience. It blends robotic execution with a familiar surgical experience, offering a new option for healthcare providers seeking flexibility in incorporating robotic technology. The system is compatible with Stryker's Triathlon Total Knee System and features a robotically enabled saw equipped with Stryker's patented active adjustment technology. This technology responds to a surgeon's hand movements and helps maintain alignment with the surgical plan in real time.

"Customer response during the limited market release has been exceptionally strong," said Keith Evans, VP/GM of Stryker's Mako and Enabling Technologies business. "As we expand the Mako portfolio, we're proud to set a new standard for what customers can expect from a handheld robotics technology – bringing together robotics, power tool expertise and a deep understanding of surgical workflows."

The system provides a familiar cutting experience without the need for cutting blocks. It offers an option for surgeons interested in adopting robotic technology while integrating easily into their existing surgical workflows. Mako RPS is built to work with Stryker's multi-specialty Q Guidance System, expanding the company's ecosystem of enabling technologies across the continuum of orthopaedic care.

"By combining robotic technology with the clinically proven Triathlon Total Knee System, Mako RPS delivers an intuitive surgical experience that builds on the implant and workflow familiarity surgeons know and trust," said Lisa Kloes, vice president and general manager of Stryker's Knee business.